Search Results

TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that the FDA advised the Company to submit a Type C meeting request to discuss evaluating a proposed Phase 2 clinical study of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID. The Company expects to submit the Type C meeting request by next week. The CDC estimates that 7.5 percent of U.S. adults have long COVID symptoms1. David Cutler, PhD, a professor of economics at Harvard University, estimates in a recent research disclosure that the total economic cost of long COVID could be as much as $3.7 trillion2. Currently, the Company is exploring the use of Bucillamine as a potential treatment for long COVID. The Company is advancing the clinical development of Bucillamine by leveraging the published research and data from its previous Phase 3 clinical trial (the “Study”) and is finalizing the regulatory and clinical package that includes a proposed Phase 2 clinical study for long COVID to present to the FDA. On July 6, 2023, the Company announced the results of its Study evaluating the safety and efficacy of oral Bucillamine in patients with mild to moderate COVID-19. Under the Study’s primary endpoint, the proportion of patients meeting a composite endpoint of hospitalization or death from time of first dose through Day 28 following randomization, there were no deaths and four hospitalizations, of which three were from the placebo arm and one from the Bucillamine low dose group (300mg/day). No hospitalizations occurred in the Bucillamine large dose group (600mg/day). The Company evaluated certain Study endpoints, including the COVID-19 clinical symptoms data (i.e. cough, fever, heart rate, and oxygen saturation). Based on preliminary analyses, the data demonstrated that for patients with oxygen saturation <96% at baseline, Bucillamine had a 29.1% improvement over placebo in time to normal oxygen saturation (SpO2). Additional analyses of the Study data may suggest Bucillamine’s potential for long COVID. A study titled “Thiol-based drugs decrease binding of SARS-CoV-2 spike protein to its receptor and inhibit SARS-CoV-2 cell entry” showed that thiol-based drugs, like Bucillamine, decrease the binding of SARS-CoV-2 spike protein to its receptor, decrease the entry efficiency of SARS-CoV-2 spike pseudotyped virus, and inhibit SARS-CoV-2 live virus infection. These findings uncovered a vulnerability of SARS-CoV-2 to thiol-based drugs and provided a rationale to test thiol-based drugs such as Bucillamine as novel treatments for COVID-19. About Revive Therapeutics Ltd. Revive Therapeutics is a life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. Revive prioritizes its drug development efforts to take advantage of several regulatory incentives awarded by the FDA, such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. Revive is also advancing the development of Psilocybin-based therapeutics through various programs. For more information, visit www.ReviveThera.com. For more information, please contact: Michael Frank, Chief Executive Officer Revive Therapeutics Ltd. Tel: 1 888 901 0036 Email: mfrank@revivethera.com Website: www.revivethera.com Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release. Cautionary Statement This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “may”, “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the the Company’s cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company's management's discussion and analysis for the three months ended September 30, 2023 ("MD&A"), dated November 29, 2023, which is available on the Company's profile at www.sedarplus.ca. Sources: “Nearly One in Five American Adults Who Have Had COVID-19 Still Have “Long COVID,” CDC, June 6, 2022, https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.htm “The Economic Cost of Long COVID: An Update,” David M. Cutler, Harvard University, July 22, 2022, https://scholar.harvard.edu/files/cutler/files/long_covid_update_7-22.pdf SOURCE

TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a corporate update on the research, clinical and regulatory initiatives with Bucillamine and its long COVID diagnostic product. Bucillamine The Company is advancing the research and development of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID and medical countermeasures, such as nerve agent exposure. Chemical Warfare - Nerve Agent Exposure Nerve agents are chemicals that affect the nervous system. Nerve agents are highly toxic regardless of the route of exposure. The main chemical nerve agents that are man-made and manufactured for use in chemical warfare are sarin, soman, tabun and VX. These nerve agents are known to be present in military stockpiles. Exposure to nerve agents can occur due to chemical warfare or accidental release from a military storage facility. Exposure to nerve agents can cause tightness of the chest, excessive salivation, abdominal cramps, diarrhea, blurred vision, tremors, and death. Currently, in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence, the Company is evaluating Bucillamine as a potential treatment for nerve agent exposure. DRDC is investigating pharmacological compounds that can mitigate nerve agent induced brain injury. Recent studies have shown that antioxidant compounds such as n-acetylcysteine (“NAC”) could be beneficial in limiting seizure activity and improving the anticonvulsant efficacy of GABA-mediating drugs such as diazepam. Bucillamine is a significantly more effective antioxidant than NAC and has the potential to provide increased efficacy against seizure activity while limiting the anticoagulant and bleeding event liability observed with NAC. The overall objective of the research project is to investigate pharmacological means for neuroprotection of GABA(A) receptors, which are required for the effectiveness of currently fielded anticonvulsant therapies. Bucillamine and NAC will be evaluated to determine the effect on GABA(A) receptor endocytosis and the effect on diazepam effectiveness in terminating seizures. Any additional antioxidant effects on seizure activity and survival will also be assessed. The results from this research partnership, if promising, will determine further studies to facilitate FDA and Health Canada approvals for the use of Bucillamine in nerve agents or organophosphate pesticide poisoning. Also, the Company may explore the potential of Bucillamine for traumatic brain injury caused by concussive or explosive forces. The research project is expected to be completed by June 2024. Long COVID The CDC estimates that 7.5 percent of U.S. adults have long COVID symptoms1. David Cutler, PhD, a professor of economics at Harvard University, estimates in a recent research disclosure that the total economic cost of long COVID could be as much as $3.7 trillion2. Currently, the Company is exploring the use of Bucillamine as a potential treatment for long COVID. The Company is advancing the clinical development of Bucillamine by leveraging the published research and data from its previous Phase 3 clinical trial (the “Study”) in preparing a regulatory and clinical package that includes a proposed Phase 2 clinical study for long COVID to present to the FDA and international health regulatory authorities. The Phase 2 study protocol has been completed, and the Company is preparing its submission to the FDA. It expects to submit it by the end of March 2024. The proposed Phase 2 clinical study is expected to be approved by the FDA in Q2-2024. As a background, on July 6, 2023, the Company announced the results of its Study evaluating the safety and efficacy of oral Bucillamine in patients with mild to moderate COVID-19. Under the Study’s primary endpoint, the proportion of patients meeting a composite endpoint of hospitalization or death from time of first dose through Day 28 following randomization, there were no deaths and four hospitalizations, of which three were from the placebo arm and one from the Bucillamine low dose group (300mg/day). No hospitalizations occurred in the Bucillamine large dose group (600mg/day). The Company evaluated certain Study endpoints, including the COVID-19 clinical symptoms data (i.e. cough, fever, heart rate, and oxygen saturation). Based on preliminary analyses, the data demonstrated that for patients with oxygen saturation <96% at baseline, Bucillamine had a 29.1% improvement over placebo in time to normal oxygen saturation (SpO2). Additional analyses of the Study data may suggest Bucillamine’s potential for long COVID. A study titled “Thiol-based drugs decrease binding of SARS-CoV-2 spike protein to its receptor and inhibit SARS-CoV-2 cell entry” showed that thiol-based drugs, like Bucillamine, decrease the binding of SARS-CoV-2 spike protein to its receptor, decrease the entry efficiency of SARS-CoV-2 spike pseudotyped virus, and inhibit SARS-CoV-2 live virus infection. These findings uncovered a vulnerability of SARS-CoV-2 to thiol-based drugs and provided a rationale to test thiol-based drugs such as Bucillamine as novel treatments for COVID-19. In addition, Revive may evaluate the potential of its proposed long COVID diagnostic product as a companion to Bucillamine. Long COVID Diagnostic Product The Company, under its wholly-owned subsidiary Revive Diagnostics Inc., is advancing the product development of a potential blood biomarker diagnostic that characterizes long COVID. The discovery of the biomarkers identified by a research team at Lawson, led by Dr. Douglas Fraser, was recently published in the journal, Molecular Medicine3. The Company entered into a license agreement with Lawson Health Research Institute for the worldwide exclusive rights to the intellectual property of novel blood biomarkers that characterize long COVID. The intellectual property includes PCT/CA2023/050145 entitled “Blood Biomarkers in Long-COVID19”; PCT/CA2023/051292 entitled “Biomarkers in Long-COVID19”; and US Provisional Patent Application No. 63/433,425 entitled “Diagnosis and Treatment of Long-COVID”. Revive and Lawson continues to work together in completing the product development and investigational plans of a qELISA laboratory test kit and a point-of-care device for rapid testing of long COVID for FDA review, feedback and acceptability. The Company expects to submit a pre-investigational device exemption meeting package with the FDA in April 2024 and have its meeting with the FDA in early Q3-2024. Currently, there is no FDA-approved clinical diagnosis of long COVID and it is estimated to occur in at least 10% of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. More than 200 symptoms have been identified with impacts on multiple organ systems4 — including fatigue, brain fog, difficulty breathing, and cardiovascular symptoms ranging from chest pain and arrhythmias to sudden cardiac death—but it remains a diagnosis of exclusion with an unknown biological basis5. About Revive Therapeutics Ltd. Revive Therapeutics is a life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. Revive prioritizes its drug development efforts to take advantage of several regulatory incentives awarded by the FDA, such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. Revive is also advancing the development of Psilocybin-based therapeutics through various programs. For more information, visit www.ReviveThera.com. For more information, please contact: Michael FrankChief Executive Officer Revive Therapeutics Ltd. Tel: 1 888 901 0036 Email: mfrank@revivethera.com Website: www.revivethera.com Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release. Cautionary Statement This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “may”, “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the the Company’s cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company's management's discussion and analysis for the three months ended September 30, 2023 ("MD&A"), dated November 29, 2023, which is available on the Company's profile at www.sedarplus.ca. Sources: “Nearly One in Five American Adults Who Have Had COVID-19 Still Have “Long COVID,” CDC, June 6, 2022, https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.htm “The Economic Cost of Long COVID: An Update,” David M. Cutler, Harvard University, July 22, 2022, https://scholar.harvard.edu/files/cutler/files/long_covid_update_7-22.pdf “Elevated vascular transformation blood biomarkers in Long-COVID indicate angiogenesis as a key pathophysiological mechanism.” Molecular Medicine 28, 122 (2022). London researchers discover novel method to diagnose long COVID | Lawson Health Research Institute (lawsonresearch.ca) Davis, H.E., McCorkell, L., Vogel, J.M. et al. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 21, 133–146 (2023). https://doi.org/10.1038/s41579-022-00846-2; access https://www.nature.com/articles/s41579-022-00846-2 “Proteins In The Blood Hint At Biological Basis Of Long COVID”, Clinical Research News, August 11, 2023, https://www.clinicalresearchnewsonline.com/news/2023/08/11/proteins-in-the-blood-hint-at-biological-basis-of-long-covid SOURCE

Vancouver, British Columbia--(Newsfile Corp. - February 26, 2024) - Atomic Minerals Corporation (TSXV: ATOM) ("ATOMIC MINERALS" or the "Company") is pleased to report optionee Kraken Energy Corp. ("Kraken Energy") has mobilized for Phase 1 drilling at the Harts Point Uranium Property ("Harts Point" or the "Property") located in San Juan County, Utah. The Phase I drilling program will explore the property from two drill pad locations over a 5-km strike length targeting the favorable uranium bearing Chinle Formation host rock where three historical oil wells returned "off-scale" radioactivity. "We are extremely excited optionee Kraken Energy is executing Phase I drilling at Harts Point," commented Clive Massey, President & CEO of Atomic Minerals. "This drilling will test the off-scale radioactivity encountered in historic oil and gas drill holes at Harts Point probing the project's exceptional potential to discover a trend of high-grade uranium deposits located within a pro-mining jurisdiction," he continued. "Harts Point is perfectly situated to capitalize on existing infrastructure and potential future milling capacity in area of known significant historical uranium production as we endeavor to establish Atomic Minerals a leader in the uranium industry," he concluded. Harts Point Property Highlights: World class uranium jurisdiction: located in the center of the Colorado Plateau, which has produced over 590 million ("M") pounds ("lbs.") U3O8 at 0.2 to 0.4% U3O8 since the 1950s1,5-8. Property consists of 324 lode mining claims on Bureau of Land Management ("BLM") ground that covers an area of 2,622 hectares ("ha") (6,480 acres). Harts Point Anticline is Analogous to the Lisbon Valley Anticline: where the Lisbon Valley Uranium District hosted 17 large uranium mines which produced approximately 80M lbs. U3O8 at 0.34% U3O8 from 1948 to 19882. The dimensions of these tabular sandstone-hosted uranium deposits range from 2 to 13 meters ("m") (7 to 43 feet) thick, 100 to 3,048 m (328 to 10,000 feet) long, and 31 to 427 m (100 to 1,400 feet) wide3. Significant Historic Uranium Production: Several historic mines located 11 km (7 miles) west of the Harts Point Property produced approximately 280,000 lbs. U3O8 at 0.3% U3O8 from the favorable Chinle Formation host rock4. The Lisbon Valley Anticline is located 31 km (19 miles) to the east of the Harts Point Property produced approximately 80M lbs. U3O8 0.34% U3O82. Historic Exploration: Three wide-spaced historic oil and gas wells on the Property (Figure 1) along the east flank of the Harts Point Anticline show 'off-scale' radioactivity within the favorable Chinle Formation host rock. Drilled between 1953 and 1980, historic drill holes 43-037-10438, 43-037-30109, and 43-037-30623 showed off-scale radioactivity readings between 2.1 to 3.7 m thickness (7 to 12 feet) from depths of 390 to 417 m (1,280 to 1,368 feet). Excellent Infrastructure: located approximately 64 km (40 miles) north of the White Mesa uranium processing facility. There is also excellent access throughout the Property, which is situated 45 km (28 miles) from the town of Monticello, Utah. Figure 1: Harts Point Property with Local Uranium Occurrences To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10252/199177_b3751fc0442c09df_002full.jpg References: Holger Albrethsen, Jr., and Frank E. McGinley (1982). Summary History of Domestic Procurement Under U.S. Atomic Energy Commission Contracts, September 1982. Chenoweth, W.L. (1990). Lisbon Valley, Utah's Premier Uranium Area, a Summary of Exploration and Ore Production. Utah Geological Survey Open File Report 188, July 1990. Gordon W. Weir and Willard P. Puffett (1981). Incomplete manuscript on stratigraphy and structural geology and uranium-vanadium and copper deposits of the Lisbon Valley area, Utah-Colorado. Open-File Report 81-39. Pages 153 to 163. United States Department of the Interior Geological Survey. Chenoweth, W.L. (1993): The geology and Production History of the Uranium deposits in the White Canyon Mining District, San Juan County, Utah, Utah Geological Survey Miscellaneous Publication 93-3. Mills, Stephanie E., and Bear Jordan (2021). Uranium and Vanadium Resources of Utah: An Update in the Era of Critical Minerals and Carbon Neutrality, Open File Report 735, Utah Geological Survey. Chenoweth, William L. (1981). The Uranium - Vanadium Deposits of the Uravan Mineral Belt and Adjacent Areas, Colorado and Utah, New Mexico Geological Society Guidebook, 32nd Field Conference, Western Slope Colorado. McLemore, Virginia T., and Willam L. Chenoweth (1989). Uranium Resources in New Mexico, Resource Map 18, New Mexico Bureau of Mines and Mineral Resources. Chenoweth, William L., and Virginia T. McLemore (1989). Uranium Resources on the Colorado Plateau in Energy Frontiers in the Rockies, Albuquerque Geological Society. The data disclosed in this news release is related to historical drilling results. Atomic has not undertaken any independent investigation of the sampling, nor has it independently analyzed the results of the historical exploration work in order to verify the results. Atomic considers these historical drill results relevant as the Company is using this data as a guide to plan exploration programs. The Company's current and future exploration work includes verification of the historical data through drilling. Qualified Person Mr. R. Tim Henneberry, P.Geo. (BC), an advisor to the Company, is the "Qualified Person" under National Instrument 43-101 responsible for the technical contents of this news release and has approved the disclosure of the technical information contained herein. About Harts Point Harts Point is located in the center of the Colorado Plateau, referred to by some as "the Athabasca Basin of the US" and is 64 kilometers ("km") (40 miles) north of the White Mesa Uranium Mill, the only fully licensed and operating conventional uranium mill in the United States. The Property consists of 324 lode mining claims on Bureau of Land Management ("BLM") ground and drill permits are in place for up to 20 exploration drill holes. Atomic Minerals has granted Kraken Energy Corp. the right to earn a 65% interest in Harts Point. Kraken Energy must complete US$1.5 million in exploration expenditures within 18 months and a further 10% interest to 75% by completing a further US$2.0 million in exploration expenditures and issuing 2 million shares to Atomic Minerals within the next 30 months. Atomic Minerals retains a 2% Net Smelter Return Royalty which can be reduced to 1% through a US$5 million payment. Upon completion of 65% or 75% interest, a joint venture will be formed. About the Company Atomic Minerals Corp. is a publicly listed exploration company on the TSX Venture Exchange, trading under the symbol ATOM, led by a highly skilled management and technical team with a proven track record in the junior mining sector. Atomic Minerals' objective is to identify exploration opportunities in regions that have been previously overlooked but are geologically similar to those with previous uranium discoveries. These under-explored areas hold immense potential and are in stable geopolitical and economic environments. Atomic Minerals' property portfolio contains uranium projects in three locations within North America, all of which have significant technical merit and or are known for hosting uranium production in the past. Three of the properties are located on the Colorado Plateau, an area which has previously produced 597 million pounds of U3O8; Three others are in the prolific Athabasca Basin region and nine uranium projects are located Northern Saskatchewan, encompassing a total exploration area of 6,495 hectares. For additional information about the Company and its projects, please visit our website at www.atomicminerals.ca. ON BEHALF OF THE BOARD OF DIRECTORS "Clive Massey" Clive H. Massey President & CEO For further information, please contact: Dave Langlais (778) 316-5105 Neither TSX Venture Exchange nor their Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements: This news release contains certain statements that may be deemed "forward-looking" statements. Forward-Looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Atomic Minerals Corporation believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-Looking statements are based on the beliefs, estimates and opinions of Atomic Minerals Corporation management on the date the statements are made. Except as required by law, Atomic Minerals Corporation undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change. SOURCE

Vancouver, British Columbia / TheNewswire / February 27, 2024:  Rock Edge Resources Ltd. (the "Company" or "Rock Edge") (CSE:REDG) announces that it has formally changed its name to Inspiration Energy Corp. and will commence trading its common shares on the Canadian Securities Exchange (“CSE”) under the new ticker symbol “ISP” at the open of trading on Thursday, February 29, 2024. The new CUSIP number will be 457702108 and new ISIN number will be CA4577021088. The Company also announces that it will not be proceeding with the second tranche of the private placement which was announced on January 29, 2024. The first tranche was closed on February 13, 2024. (see news release February 13, 2024) About Rock Edge Resources Ltd. Rock Edge Resources Ltd. is engaged in the business of mineral exploration and the acquisition of mineral property assets in Canada.  Its objective is to locate and develop properties of merit and to conduct its exploration on the Company’s exploration properties. For more information, please refer to the Company's information available on SEDAR+ (www.sedarplus.ca). On Behalf of the Board of Directors Charles Desjardins Chief Executive Officer, President and Director Phone #604-808-3156 Email: info@rockedgeresources.com Neither the Canadian Stock Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this news release. FORWARD LOOKING STATEMENTS: This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions, including with respect to the Company’s ability or intention to change its corporate name, as described above. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Investors are cautioned that these forward looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected. These forward -looking statements are made as of the date hereof and, except as required under applicable securities legislation, the Company does not assume any obligation to update or revise them to reflect new events or circumstances. All of the forward-looking statements made in this press release are qualified by these cautionary statements and by those made in our filings with SEDAR+ in Canada (available at WWW.SEDARPLUS.CA). SOURCE

Vancouver, British Columbia--(Newsfile Corp. - February 27, 2024) - Forum Energy Metals Corp. (TSXV: FMC) (OTCQB: FDCFF) ("Forum" or the "Company") announces significant gold assay values associated with high-grade uranium mineralization on the Tatiggaq deposit in the Thelon Basin at its newly re-named Aberdeen uranium project. Forum holds a 100% interest in 95,500 hectares of ground adjacent to Orano's 133 million pound Kiggavik uranium deposit* located 100 km west of Baker Lake, Nunavut. Drill core from two holes drilled into the Main and West zones of Tatiggaq were re-assayed for gold (Figure1). HIGHLIGHTS TAT23-002 hosts 0.7 g/t Au over 11.1 m (148.5 - 159.6 m) including 1.0 g/t Au over 3.1 m including 2.6 g/t Au over 1.5 m TAT23-003 hosts 0.7 g/t Au over 24.6 m (129.5 - 154.1 m) including 2.5 g/t Au over 2.3 m incl. 9.3 g/t Au over 0.3 m including 1.6 g/t Au over 0.8 m including 1.1 g/t Au over 1.5 m Dr. Rebecca Hunter, Forum's VP, Exploration stated, "Gold associated with uranium mineralization at Tatiggaq adds to the economic potential of Forum's high grade, unconformity-style deposit in the Thelon Basin. Forum is well funded to advance this discovery with a 10,000-metre drill program planned for this summer. Forum will conduct metallurgical tests upon completion of the drill program to determine gold and uranium recoveries. This development shows the immense potential of the northeast Thelon to host additional gold-bearing, unconformity-related uranium deposit systems." Tatiggaq Figure 1 shows the main east-northeast structures (Thelon and Judge Sissons faults) as well as the numerous, sub-parallel subsidiary east-northeast structures interpreted to control uranium mineralization on Orano's and Forum's property. Figure 2 is a plan map of the Tatiggaq gravity anomaly. The high gold values are found in the mineralized intervals at both Tatiggaq Main and West zones. Figure 3 shows the gold values superimposed on the mineralized interval in TAT23-002. While the highest gold values are correlated with the highest uranium intercepts, significant gold values are present as an envelope to uranium mineralization (see the following link to the Company website for detailed analysis:Au_results_table for website TAT23-002 was drilled into the Tatiggaq Main Zone and TAT23-003 was drilled 200 m to the SW along strike into the Tatiggaq West Zone. Both drill holes intersected significant uranium mineralization and coincident gold mineralization. TAT23-004 located in between these two drill holes (Figure 2) is currently in the lab for gold assay. TAT23-002: 2.25% U3O8 over 11.1 m (148.5 - 159.6 m) and 0.7 g/t Au including 3.32%% U3O8 over 3.1 m (152.2 - 155.3 m) and 1.0 g/t Au including 7.27% U3O8 over 1.5 m (156.9 - 158.4 m) and 2.6 g/t Au TAT23-003: 0.28% U3O8 over 24.6 m (129.5 - 154.1 m) and 0.7 g/t Au including 0.36% U3O8 over 2.3 m (129.5 - 131.8 m) and 2.5 g/t Au including 9.3 g/t over 0.3 m including 1.10% U3O8 over 0.8 m (136.0 - 136.8 m) and 1.6 g/t Au and 1.1 g/t Au over 1.5 m (149.3 - 150.8 m) Table 1 2023 Drill Hole Data. UTM collar coordinates are in datum WGS84 Zn 14N. Table 2 - Au assay results for TUR23-002. Table 2 - Au assay results for TUR23-003. *Source: Areva Resources Canada Inc., The Kiggavik Project, Project Proposal, November 2008 and Kiggavik Popular Summary, April, 2012 submission to the Nunavut Impact Review Board. Quality Assurance/Quality Control Geochemical analysis was conducted at the Saskatchewan Research Council Geoanalytical Laboratory in Saskatoon, Saskatchewan. Systematic 10 cm split (basement) and 10 m chip composite samples (sandstone) were analysed using ICP-MS Exploration Package for sandstone and basement rocks (ICP-MS1 and 2). Assay samples were analysed using the ICP-OES package (ICP1) with the addition of the U3O8 wt% and Au fire assay analysis measured in ppb. One Au sample was re-analyzed using gravimetric analysis to confirm the high-grade result. Mineralized samples were split into half core samples ranging from 10 to 50 cm in thickness except shoulder regions were locally up to 90 cm and all samples were grouped based on similar radioactivity using a hand-held scintillometer. Duplicates were taken every 20 m and were within acceptable limits for field rock samples. Rebecca Hunter, PhD., P.Geo., Forum's Vice President of Exploration and Qualified Person under National Instrument 43-101, has reviewed and approved the contents of this news release. Figure 1 The Thelon Basin is a geologic analogue to the Athabasca Basin in Saskatchewan. Orano's uranium deposits are along the same controlling structures as Forum's Tatiggaq deposit and over 20 other targets are present within the project, which could host additional uranium deposits similar to the Athabasca Basin. To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/4908/199289_4027794cb4632817_003full.jpg Figure 2 The Tatiggaq gravity anomaly showing the location of the Tatiggaq West and Main zones, historical drilling and the 2023 drill holes. Au assay results are for TAT23-002 and TAT23-003. TAT23-004 is still pending. Inset Map: close-up of 2023 drilling. To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/4908/199289_4027794cb4632817_004full.jpg Figure 3 TAT23-002 drill core from the mineralized section (142.7 to 165.5 m). Scintillometer readings are written on the core boxes in counts per second and were measured using a digital, hand-held CT-007M scintillometer by Environmental Instruments Canada Inc. The fire assay Au values are shown within the U assay intervals. To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/4908/199289_4027794cb4632817_005full.jpg About Forum Energy Metals Forum Energy Metals Corp. (TSXV: FMC) (OTCQB: FDCFF) is focused on uranium exploration in Canada. Forum holds interests in 76,421 hectares in the Athabasca Basin, Saskatchewan and 95,519 hectares in the Thelon Basin, Nunavut, a geologic analogue to the Athabasca for high grade, unconformity-related uranium deposits. In addition, Forum holds a strategic portfolio of energy metal projects - copper, nickel, PGM, zinc and cobalt in Saskatchewan and Idaho. For further information: https://www.forumenergymetals.com. This press release contains forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause Forum's actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information. Such factors include but are not limited to: uncertainties related to the historical data, the work expenditure commitments; the ability to raise sufficient capital to fund future exploration or development programs; changes in economic conditions or financial markets; changes commodity prices, litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; technological or operational difficulties or an inability to obtain permits required in connection with maintaining or advancing its exploration projects. ON BEHALF OF THE BOARD OF DIRECTORS Richard J. Mazur, P.Geo. President & CEO Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. For further information contact: Rick Mazur, P.Geo., President & CEO mazur@forumenergymetals.com Tel: 604-630-1585 SOURCE

Vancouver, British Columbia--(Newsfile Corp. - March 1, 2023) - You are welcome to join Forum Energy Metals (TSXV: FMC) (OTCQB: FDCFF) at the Red Cloud Pre-PDAC Mining Showcase on Thursday, March 2nd and Friday, March 3rd followed by the Investor Exchange Booth #2825 at the 2023 PDAC, being held at the Metro Toronto Convention Centre, Sunday March 5th through Wednesday March 8th. Technical meetings with management and partnering inquiries on Forum's portfolio of uranium, copper, nickel and cobalt projects in Saskatchewan, Nunavut and Idaho can be arranged with Dr. Rebecca Hunter, Vice President, Exploration and the Forum team at our booth, or contact: Rick Mazur, President & CEO, to arrange a time for an off site meeting mazur@forumenergymetals.com; 604-630-1585 Dr. Rebecca Hunter, VP, Exploration will be presenting at the Red Cloud Pre-PDAC Mining Showcase at 2:10pm on Thursday, March 2nd. Dr. Hunter will review the Company's recent uranium drill program in the Athabasca Basin, the advancement of its Thelon Basin uranium acquisition of uranium deposits formerly discovered by Cameco Corporation and review of its energy metal properties - copper, nickel and cobalt. About Forum Energy Metals Forum Energy Metals Corp. (TSXV: FMC) (OTCQB: FDCFF) is a diversified energy metal company with uranium, copper, nickel, and cobalt projects in Saskatchewan, Canada's Number One Rated mining province for exploration and development, a strategic uranium land position in Nunavut and a strategic cobalt land position in the Idaho Cobalt Belt. For further information: www.forumenergymetals.com ON BEHALF OF THE BOARD OF DIRECTORS Richard J. Mazur, P.Geo.President & CEO Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. For further information contact: Rick Mazur, P.Geo., President & CEOmazur@forumenergymetals.comTel: 604-630-1585 SOURCE

Vancouver, British Columbia--(Newsfile Corp. - February 12, 2024) - Forum Energy Metals Corp. (TSXV: FMC) (OTCQB: FDCFF) ("Forum" or the "Company") is pleased to announce the appointment of Brian Christie to the Board of Directors of Forum Energy Metals. Rick Mazur, President & CEO stated, "Brian was one of the first Mining Analysts to recognize the potential of the Thelon Basin when Forum first staked mineral claims adjacent to the Orano/UEC/Denison Kiggavik deposit in Nunavut in 2006. Following his seventeen-year career as a Mining Analyst, Brian has gained great insight into operations in Nunavut through his ten-year career as Vice President, Investor Relations at Agnico Eagle Mines when Agnico put the Meadowbank gold mine into production." Mr. Mazur further stated, "David Cowan has stepped down from the Board of Directors and will remain on Forum's Advisory Board as Legal Advisor. David has been on the Board since the Company's inception in 2004 and we look forward to his continued counsel." "I am excited to be joining Forum's Board. The Company has done a great job of maintaining and building a large prospective land package in Nunavut near the Kiggavik deposit. Results from last year's exploration program indicate that the Company is well positioned to make a significant new discovery in the region in 2024", said Mr. Christie. Brian served as the Vice President of Investor Relations at Agnico Eagle Mines from December 2012 until his retirement in July 2022. During his tenure at Agnico Eagle, the company was consistently recognized as having one of the top Investor Relations programs across all industries in Canada. Mr. Christie is currently retained by Agnico Eagle as a Senior Advisor, Investor Relations. Before joining Agnico Eagle, he worked for over 17 years in the investment industry, primarily as a mining analyst covering gold, uranium and base metal companies. From 2005 until 2009, he covered several domestic and international uranium companies at National Bank Financial. Prior to working in the investment industry, Mr. Christie spent 13 years in the mining industry as a geologist for a variety of mining companies, including Homestake, Billiton, Falconbridge Copper and Newmont Mining. Mr. Christie holds a BSc. in Geology (University of Toronto) and an MSc. in Geology (Queen's University) and is a member of the Canadian Investor Relations Institute (CIRI) and the National Investor Relations Institute (NIRI). He currently serves as the Chair of Fury Gold Mines Limited and is also an Independent Director of Wallbridge Mining Company Limited. In connection with his appointment, the Company has granted to Brian Christie incentive stock options to purchase up to an aggregate of 300,000 common shares exercisable on or before February 12, 2029 at a price of $0.15 per share. About Forum Energy Metals Forum Energy Metals Corp. (TSXV: FMC) (OTCQB: FDCFF) is focused on the discovery of high-grade unconformity-related uranium deposits in the Athabasca Basin, Saskatchewan and the Thelon Basin, Nunavut. In addition, Forum holds a diversified energy metal portfolio of copper, nickel, and cobalt projects in Saskatchewan and Idaho. For further information: https://www.forumenergymetals.com. ON BEHALF OF THE BOARD OF DIRECTORS Richard J. Mazur, P.Geo.President & CEO Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. For further information contact: Rick Mazur, P.Geo., President & CEO mazur@forumenergymetals.com Tel: 604-630-1585 SOURCE

Wednesday Feb 7th @7 pm ET FTMIG goes live with Golden Goliath CEO and expert geologist with news of their private placement and advancements made on their Manicouagan Project. View here

VICTORIA, BC / ACCESSWIRE / February 5, 2024 / Boron One Holdings Inc. ("Boron One" or the "Company") (TSXV:BONE), a company dedicated to the decarbonization of Planet Earth through the responsible utilization of its boron assets, is pleased to report that it has been granted a new exploration license by the Serbian Ministry of Mining and Energy for the Company's wholly owned Piskanja Boron Project. This new 3-year license ensures Boron One's continued exclusive rights to the Piskanja property, as the Company progresses through the mineral exploitation approval process for Piskanja (the "Approval Process") with the Mining Ministry. As previously reported by the Company, it has received a "Certificate of Reserves" from the Mining Ministry as the first requisite step in the Approval Process, and is readying the mandatory documentation for submission in order to receive the "Approval of the Exploitation Field" as the next step in the Approval Process. Tim Daniels, CEO of Boron One added, "Requesting a new exploration license was prudent to ensure continuity in our exclusive rights to the Piskanja deposit while we are in process to complete the exploitation licensing procedure. Our original Piskanja exploration license had expired, but exclusive exploitation rights do not commence until we receive an Approval of the Exploitation Field from the Ministry, prompting this interim action to ensure our uninterrupted rights to Piskanja between those two events." Tim Daniels continued, "Additionally, this new exploration license affords us an opportunity to attempt to expand the extent of the known mineral resource at Piskanja, as there remain unexplored regions of the property that lie outside the currently known mineral body footprint, but within the boundaries of the Piskanja exploration license area." About the Piskanja Boron Project Piskanja is Boron One Holdings Inc.'s wholly owned boron deposit with a Measured Mineral Resource of 1.39 million tonnes (averaging 35.59% B2O3), an Indicated Mineral Resource of 5.48 million tonnes (averaging 34.05% B2O3), and an Inferred Mineral Resource of 284.7 thousand tonnes (averaging 39.59% B2O3), calculated in accordance with the Canadian Institute of Mining Definition Standards on Mineral Resources and Reserves (CIM Standards), as disclosed in the Company's report titled, "Technical Report and Preliminary Economic Assessment For The Piskanja Borate Project, Serbia, June 24, 2022". The responsible person for the PEA and the Mineral Resource Estimate contained within, is Prof. Miodrag Banješević PhD. P.Geo, EurGeol, a Qualified Person in accordance with the CIM Definition Standards on Mineral Resources and Reserves (CIM Standards), and independent of Boron One Holdings Inc. On behalf of the Board of Directors, Tim Daniels About Boron One Holdings Inc. (formerly known as Erin Ventures Inc.) Boron One Holdings Inc. is a leading company dedicated to advancing the decarbonization of our planet through the responsible utilization of its wholly owned boron assets. With a commitment to environmental stewardship and sustainability, Boron One aims to play a crucial role in reducing the carbon footprint and supporting a cleaner, greener future. Headquartered in Victoria, B.C., Canada, Boron One's shares are traded on the TSX Venture Exchange under the symbol "BONE". For detailed information please see Boron One's website at www.boronone.com or the Company's filed documents at https://www.sedarplus.ca/. For further information, please contact: Boron's Public Quotations: Qualified Persons Nenad Rakic, EurGeol, Piskanja Project Field Manager, a qualified person as defined by NI 43-101, has reviewed the technical information that forms the basis for this news release, and has approved the disclosure herein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. For Boron One Holdings Inc. Investors Certain statements made in this press release that are not based on historical information are forward-looking statements that involve substantial known and unknown risks and uncertainties. This press release contains express or implied forward-looking statements relating to, among other things, Boron One's expectations concerning management's plans, objectives and strategies, including its plans for advancing the Company's Piskanja Project through to an exploitation license. These statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Factors that could cause actual results to differ materially from any forward-looking statement include, but are not limited to, failure to convert estimated mineral resources to reserves, capital and operating costs varying significantly from estimates, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, political risks, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects and the other risks involved in the mineral exploration and development industry. Boron One Holdings Inc. undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise except as expressly required by applicable securities law. Further information regarding the uncertainties and risks can be found in the disclosure documents filed by Boron One with the securities regulatory authorities, available at www.sedar.com. These and other factors made in public disclosures and filings by the Company should be considered carefully. Mineral resources are not mineral reserves and do not have demonstrated economic viability. "Inferred Resources" have a great amount of uncertainty as to their existence, and economic and legal feasibility. Investors are cautioned not to assume that all or any part of an inferred mineral resource reported in this news release will ever be upgraded to a higher category or to reserves. U.S. persons are advised that while mineral resources are recognized under Canadian regulations, the U.S. Securities and Exchange Commission does not recognize them. U.S. persons are also cautioned not to assume that all or any part of an inferred mineral resource is economically or legally mineable. SOURCE

VANCOUVER, BC / ACCESSWIRE / February 5, 2024 / Pegasus Resources Inc. (TSX-V:PEGA)(Frankfurt:0QS0)(OTC/Pink Sheet symbol:SLTFF) (the "Company" or "Pegasus") proudly announces the appointment of Mr. Mike Magrum, P. Eng, to the Company's Advisory Board. Mike Magrum, P.Eng. is a graduate of the Haileybury School of Mines and the University of Alaska with a degree in Geological Engineering. His professional career spans almost 50 years working in most commodities, particularly uranium. The work has carried him across North America, Central America and South America. He has also worked extensively in the southern countries in Africa. Mike is a former president of the Northwest Territories Chamber of Mines and a former director of the Prospectors and Developers Association of Canada (PDAC). He has served in senior management and as a director and officer of a number of Canadian public companies. He was part of the Terra Ventures Inc. team, which was a partner in the Roughrider uranium deposit discovery in the Athabasca Basin in Saskatchewan. The deposit was bought by Rio Tinto and subsequently acquired by Uranium Energy Corp. He was also the Chief Operating Officer of Xemplar Energy, a significant uranium explorer in Namibia. The company at its peak had a market cap in excess of $1 billion dollars. "We are delighted to welcome Mr. Mike Magrum to our Advisory Board," CEO Christian Timmins stated. "With nearly five decades of expertise, especially in uranium exploration, his strategic insights will be CEO Christian Timmins stated. "With nearly five decades of expertise, especially in uranium exploration, his strategic insights will be invaluable as we navigate and advance our projects at Pegasus. Pegasus also wishes to announce that pursuant to its stock option plan; the Company has granted incentive stock options to certain directors and consultants to purchase a total of 250,000 common shares in the capital stock of the Company exercisable for a period of two years at a price of $0.215 per share. About Pegasus Resources Inc. Pegasus Resources Inc. is a diversified Junior Canadian Mineral Exploration Company with a focus on uranium, gold, and base metal properties in North America. The Company is also actively pursuing the right opportunity in other resources to enhance shareholder value. For additional information, please visit the Company at www.pegasusresourcesinc.com. On Behalf of the Board of Directors: Christian Timmins President, CEO and Director Pegasus Resources Inc. 700 - 838 West Hastings Street Vancouver, BC V6C 0A6 PH: 1-403-597-3410 X: https://twitter.com/MrChris_Timmins X: https://twitter.com/pegasusresinc E: info@pegasusresourcesinc.com Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release. Forward-Looking Statements Statements included in this announcement, including statements concerning the Company's plans, intentions, and expectations, which are not historical in nature are intended to be, and are hereby identified as, "forward-looking statements." Forward-looking statements may be identified by words including "anticipates," "believes," "intends," "estimates," "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. SOURCE

VANCOUVER, BC / ACCESSWIRE / February 1, 2024 / Pegasus Resources Inc. (TSX-V:PEGA)(Frankfurt:0QS0)(OTC Pink Sheet symbol:SLTFF) (the "Company" or "Pegasus") proudly announces the appointment of Mr. Derrick Strickland, P. Geo, MBA, as a new member of the Board of Directors. Derrick Strickland, P. Geo, MBA, has over 35 years of involvement in all aspects of the exploration industry, actively working as a geological and corporate advisor. Mr. Strickland has been self-employed for over 23 years. He is an experienced leader, founder, director, CEO, and Vice President to over 20 publicly traded companies. His work over the last three decades has been on six continents, specializing in remote locations, instituting quality assurance programs, provision of on the ground geological technical execution and know-how, and expertise for both private and publicly traded resource companies. He has extensive practice in the areas of corporate governance, current regulatory regimes, compliance, and disclosure matters (NI 43-101). Mr. Strickland's international exposure encompasses a range of commodities, including base metals, gold, uranium, diamonds, potash and copper in numerous deposit types and settings, with an eye to other specialty minerals and unique opportunities. Mr. Strickland's diverse experience makes him an asset in all geological and cultural settings. Mr. Strickland's extensive network and industry engagement has seen him elected as a past director of both the Prospectors & Developers Association of Canada (PDAC) and the Association for Mineral Exploration B.C. (AME). "We are thrilled to welcome Mr. Strickland to our Board of Directors during this crucial juncture for Pegasus," CEO Christian Timmins stated. "Derrick's extensive geologic experience and knowledge adds tremendous depth to our leadership team. His expertise align seamlessly with our vision, and we look forward to leveraging his insights to execute our exploration in Utah and the Athabasca Basin." Pegasus Resources also announces the resignation of Mr. Lorne McCarthy from the Board of Directors. The Company would like to thank Mr. McCarthy for his valuable contributions during his tenure and wish him all the success in his future endeavours. These changes in the Board of Directors align with Pegasus' commitment to fostering a knowledgeable and experienced leadership team to guide the Company through its exploration activities and beyond. About Pegasus Resources Inc. Pegasus Resources Inc. is a diversified Junior Canadian Mineral Exploration Company with a focus on uranium, gold, and base metal properties in North America. The Company is also actively pursuing the right opportunity in other resources to enhance shareholder value. For additional information, please visit the Company at www.pegasusresourcesinc.com. On Behalf of the Board of Directors: Christian Timmins President, CEO and Director Pegasus Resources Inc. 700 - 838 West Hastings Street Vancouver, BC V6C 0A6 PH: 1-403-597-3410 X: https://twitter.com/MrChris_Timmins X: https://twitter.com/pegasusresinc E: info@pegasusresourcesinc.com Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release. Forward-Looking Statements Statements included in this announcement, including statements concerning the Company's plans, intentions, and expectations, which are not historical in nature are intended to be, and are hereby identified as, "forward-looking statements." Forward-looking statements may be identified by words including "anticipates," "believes," "intends," "estimates," "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. SOURCE